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CALCIFEROL IN THE TREATMENT OF SARCOIDOSIS*
CARL T. NELSON, M.D.
Several reports describing the use of large doses of calciferol (vitamin D2)
in the treatment of sarcoidosis have recently been published (1—6). The thera-
peutic trial of calciferol in this disease seems to have been stimulated by the
recognized effectiveness of this compound in the treatment of lupus vulgaris—
probably on the assumption that sarcoidosis is also a form of tuberculosis. Al-
though occasional instances have been cited in which the treatment is of no
value (2, 7), most of the data available thus far seem to show that calciferol
exerts a favorable effect on the course of sarcoidosis. In general, however, these
conclusions have been reached by observing the results of treatment in selected
single cases or in relatively small groups of cases without the use of comparable
untreated controls.
As far as can be determined, no reports have yet appeared which directly
compare the effects of calciferol therapy with the results observed in a similar
group of sarcoid patients who have received no treatment. A comparison of this
sort might be desirable, particularly since sarcoidosis tends to regress spon-
taneously and since the natural course is toward a state of ultimate remission.
An opportunity to undertake such an investigation, using a group of untreated
controls, was presented during a recent clinical study of sarcoidosis (8). The
purpose of this communication is to summarize the results of these observations
and to indicate how the findings differ from those of the reports mentioned.
METHODS AND MATERIALS
All patients with sarcoidosis included in this study were judged at the outset
to be in an active stage of the disease. In most cases dermatologic manifestations
of sarcoid were present but in some the presenting or most disturbing symptoms
were those of systemic involvement. The diagnosis of sarcoid was confirmed in
each instance by biopsy of the affected tissues and further confirmation was ob-
tained by repeated physical examinations, blood chemical studies and roent-
genographic surveys. Tuberculosis was ruled out by microscopic examination
and appropriate cultural or animal inoculation studies of tissue biopsies. Sar-
coidosis was considered to be active when lesions of the skin or mucous mem-
branes, uveitis, superficial glandular enlargement, or swelling of the salivary or
lacrimal glands persisted, or when there was evidence of progression of hilar
adenopathy, parenchymal pulmonary infiltrations, or bone lesions. The disease
was classified as inactive or in remission when the cutanous, mucosal, ocular
and glandular involvement had obviously subsided or disappeared entirely, and
when there was no further progression of bone or chest lesions seen roentgeno-
graphically.
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Sixteen patients who satisfied the criteria for sarcoid activity made up this
study. Fifteen were Negro and oniy one was white. Eight of these individual5
received 120,000 units (3 mg.) of calciferol' daily in a mixture of equal parts of
ethyl alcohol and propylene glycol. This dosage was continued for 12 months
unless clinical remission supervened. In that event, the calciferol intake was
reduced to 60,000 units daily for the remainder of the treatment period.
In only one case was it necessary to interrupt treatment because of vitamin
D2 toxicity. This patient (case No.8) noted headache, dizziness, nausea, conjuncti-
vitis, flank pain and accentuation of the cutaneous sarcoid lesions approximately
three weeks after the start of therapy. The serum calcium was 14.4 mg. per cent
and the urinary Sulkowitch reaction was positive. Calciferol administration was
discontinued, and all symptoms gradually subsided. Seven weeks later, treat-
ment with 60,000 units of calciferol per day was started. This daily dosage was
tolerated well and was continued until twelve months of therapy had been given.
Eight other patients with approximately the same degree of active sarcoid
involvement as those receiving calciferol served as the untreated control group.
From time to time during the period of observation, these individuals received
a placebo mixture of ethyl alcohol, propylene glycol, and distilled water, 2 cubic
centimeters daily. For the most part, however, the controls did not have even
the doubtful benefit of this psychotherapy. Each patient in the control and
treated groups was observed at irregular intervals for 12 months after inclusion
in this study. At the end of that time a final clinical evaluation of each case was
made and recorded.
RESULTS
The results of these studies are summarized in Table 1. The data show that
four clinical remissions occurred during the period of observation in the eight
sarcoid patients who received calciferol. At the same time, four remissions also
were noted in the eight patients who received no treatment. These findings sug-
gest that calciferol in the amounts administered was of little or no benefit in the
treatment of these cases of sarcoidosis. While it is true that the remissions oc-
curred on the average somewhat sooner in the treated cases, the difference be-
tween the two groups in this respect is not great and presumably has no signifi-
cance in so small a series. At the present writing no additional remissions and no
relapses of clinically arrested cases have been found in either group.
The results of calciferol therapy obtained in this study are much less gratifying
than those heretofore reported in sarcoidosis. Several possible explanations for
such divergent findings come to mind. Errors inherent in small series, failure to
employ adequate controls, differences in the types of cases treated, and variations
in the amount of treatment all may contribute to the results. Moreover, it should
be remembered that 15 of the 16 patients included in this series were Negroes.
Up to now the studies on the effectiveness of calciferol in sardoidosis have been
'The eaJeiferol used in this work was supplied through the courtesy of Winthrop-Stearns,
Inc., New York 13, N.Y.
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carried out almost entirely in white patients. While there is no clear-cut evidence
that the disease in the Negro differs fundamentally from that encountered in
other racial types, it still may be that sarcoidosis in the Negro constitutes a
special problem (9).
TABLE 1
Comparison of clinicat data in eight calciferol-treated and eight untreated eases of sarcoidosis
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Remission after 7 mos.
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No improvement
+ = present; ± = equivocal; 0 = absent.
* At start of observation period.
f Including (1) mucous membrane lesions; (2) enlarged spleen; (3) VII nerve weak-
ness; (4) involvement of tonsils; (5) enlarged liver.
SUMMARY
1. Eight individuals with active sarcoidosis were treated with large doses of
calciferol (vitamin D2). Eight other patients with similar involvement served as
untreated controls.
2. During an observation period of 12 months, four clinical remissions occurred
in the treated group, and four were also noted in the control group.
3. On the basis of these observations it was concluded that calciferol was of
no value in the treatment of these cases of sarcoidosis.
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